Scilex Holding Company (SCLX), a leading pharmaceutical company, has released its preliminary unaudited financial results for the one month ended June 30, 2023, quarter ended June 30, 2023, and year-to-date as of June 30, 2023. Although these figures are subject to change, they provide a glimpse into the company's performance during the specified periods. The company's independent auditor has not yet reviewed or audited these results, and the actual figures may differ. However, the preliminary data showcases remarkable growth in both net income and revenue, signaling a positive outlook for Scilex Holding Company.
Significant Growth in ZTlido Gross and Net Sales
Scilex Holding Company estimates that ZTlido, its flagship product, achieved impressive growth in both gross and net sales across various timeframes. In June 2023, ZTlido gross sales were projected to be in the range of $13.5 million to $14.5 million, reflecting a remarkable 82% to 96% growth compared to June 2022, which saw $7.4 million in sales. Similarly, for the quarter ended June 2023, ZTlido gross sales were estimated to be between $37.5 million and $39.0 million, representing a substantial growth range of 79% to 86% compared to the same period in the previous year ($21.0 million). Year-to-date June 2023 figures indicate ZTlido gross sales in the range of $64.2 million to $67.3 million, showcasing a remarkable growth range of 63% to 71% when compared to year-to-date June 2022 ($39.4 million).
Moreover, ZTlido net sales also witnessed substantial growth. In June 2023, ZTlido net sales were estimated to be between $4.0 million and $5.1 million, displaying growth of 21% to 54% when compared to June 2022 ($3.3 million). The quarter ended June 2023 is expected to yield ZTlido net sales ranging from $11.2 million to $13.6 million, representing growth of 42% to 72% compared to the same period in the previous year ($7.9 million). Year-to-date June 2023 figures project ZTlido net sales between $20.5 million and $23.0 million, displaying growth in the range of 39% to 56% when compared to year-to-date June 2022 ($14.7 million).
Remarkable Growth in Total Product Sales
Scilex Holding Company's total product sales, including ZTlido and other offerings, also witnessed substantial growth during the specified periods. For June 2023, total product gross sales were projected to be in the range of $14.0 million to $15.0 million, displaying an impressive growth range of 89% to 103% compared to June 2022 ($7.4 million). Similarly, for the quarter ended June 2023, total product gross sales were estimated between $39.0 million and $40.0 million, indicating a substantial growth range of 86% to 90% when compared to the same period in the previous year ($21.0 million). Year-to-date June 2023 figures suggest total product gross sales between $65.6 million and $69.0 million, showcasing growth in the range of 66% to 75% when compared to year-to-date June 2022 ($39.4 million).
Furthermore, total product net sales also demonstrated remarkable growth. In June 2023, total product net sales were estimated to be in the range of $4.2 million to $5.2 million, representing growth of 27% to 57% compared to June 2022 ($3.3 million). The quarter ended June 2023 is expected to yield total product net sales ranging from $12.0 million to $14.0 million, displaying growth in the range of 52% to 77% compared to the same period in the previous year ($7.9 million). Year-to-date June 2023 figures project total product net sales between $20.8 million and $24.0 million, indicating growth in the range of 41% to 63% when compared to year-to-date June 2022 ($14.7 million).